Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.76% | 69.68% | 74.08% | 73.38% | 70.20% |
| Total Depreciation and Amortization | -42.62% | -27.88% | -22.31% | 130.41% | 405.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 40.16% | -83.96% | -83.88% | -84.97% | -88.98% |
| Change in Net Operating Assets | -226.59% | -167.55% | -135.21% | -123.76% | 95.69% |
| Cash from Operations | -134.18% | -45.89% | 24.34% | 49.95% | 70.12% |
| Capital Expenditure | 92.47% | 89.53% | -- | 107.43% | -1,618.82% |
| Sale of Property, Plant, and Equipment | -181.20% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 83.58% | 91.24% | 101.66% | 115.39% | -1,462.35% |
| Total Debt Issued | 2,976.92% | 2,976.92% | -70.00% | -- | -- |
| Total Debt Repaid | 76.34% | -366.85% | -682.48% | -1,895.74% | -2,116.67% |
| Issuance of Common Stock | 87.28% | 165.44% | 165.44% | 23.93% | -69.21% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -184.25% | -171.19% | -71.56% | 4.82% | 61.26% |
| Cash from Financing | 177.23% | 248.43% | 146.09% | 16.02% | -71.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 445.92% | 271.93% | 139.53% | 161.51% | -218.54% |